Feasibility and efficacy of low‐dose pegfilgrastim for CD34+ cell mobilization in lymphoma
Journal of Clinical Apheresis2020Vol. 35(5), pp. 413–419
Citations Over Time
Hideki Goto, Daisuke Hidaka, Satoshi Yamamoto, Koji Hayasaka, Rie Michimata, Ikuko Kagawa, Kana Sunagoya, Hiroaki Iijima, Eiko Hayase, Souichi Shiratori, Kohei Okada, Junichi Sugita, Masahiro Onozawa, Daigo Hashimoto, Kaoru Kahata, Katsuya Fujimoto, Tomoyuki Endo, Chikara Shimizu, Takanori Teshima, North Japan Hematology Study Group (NJHSG)
Abstract
Our data indicated that a single dose of 3.6 mg pegfilgrastim on day 7 after chemotherapy safely and effectively mobilized CD34+ cells.
Related Papers
- → Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: a multicenterdose-finding study in women with breast cancer(2002)291 cited
- → A Combined Analysis of Average Relative Dose Intensity in the Chemotherapy of Solid Tumors with Pegfilgrastim or Filgrastim Support(2005)3 cited
- → Pegfilgrastim and filgrastim patterns of use in community oncology practices: Results of the ACCEPT study(2005)3 cited
- → Pegfilgrastim (Neulasta®) Vs. Tbo-Filgrastim (Granix®) Post Autologous Transplant(2018)
- → Comparison of Short Acting versus Long Acting Filgrastim for Reduction of Chemotherapy Induced Febrile Neutropenia(2022)